Walleye Capital LLC increased its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 69.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 174,581 shares of the biotechnology company's stock after acquiring an additional 71,439 shares during the quarter. Walleye Capital LLC owned approximately 0.31% of Astria Therapeutics worth $1,922,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Quest Partners LLC grew its holdings in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Astria Therapeutics during the third quarter valued at about $155,000. Hsbc Holdings PLC acquired a new stake in Astria Therapeutics in the second quarter worth about $171,000. Price T Rowe Associates Inc. MD bought a new position in Astria Therapeutics in the 1st quarter valued at about $200,000. Finally, Intech Investment Management LLC acquired a new position in Astria Therapeutics during the 3rd quarter valued at about $228,000. Institutional investors own 98.98% of the company's stock.
Astria Therapeutics Trading Down 1.2 %
Shares of NASDAQ ATXS traded down $0.12 during mid-day trading on Thursday, hitting $10.02. 974,125 shares of the company traded hands, compared to its average volume of 599,147. The business has a 50 day moving average of $11.01 and a two-hundred day moving average of $10.65. Astria Therapeutics, Inc. has a 1 year low of $4.87 and a 1 year high of $16.90.
Analyst Upgrades and Downgrades
ATXS has been the topic of a number of research analyst reports. Wedbush reiterated an "outperform" rating and set a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, November 14th. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Finally, Oppenheimer lifted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Astria Therapeutics has a consensus rating of "Buy" and a consensus price target of $25.60.
View Our Latest Stock Analysis on ATXS
About Astria Therapeutics
(
Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
